Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group (Q73190394)
Jump to navigation
Jump to search
scientific article published on 01 November 2000
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group |
scientific article published on 01 November 2000 |
Statements
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group (English)
J M Nabholtz
A Buzdar
M Pollak
W Harwin
G Burton
A Mangalik
M Steinberg
A Webster
1 November 2000